/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Olema is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of next-generation targeted therapies for breast cancer and beyond. We are advancing our pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance.
$9.82
$0.08 (-0.81%)
EOD Sep 18, 2026
Negative free cash flow of -$147M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$205M
▼ -25.5% YoY
Op. Margin
—
ROIC
-41.07%
▲ +2.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$165M
▼ -40.4% YoY
Op. Cash Flow (TTM)
-$165M
▼ -40.6% YoY
Net Debt
-$460M
Net Cash Position
Cash & Equiv.
$461M
Continue Research
SourceComputed from the 10-Q filed 10 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 11 Aug 2026. How this is calculated.
Price from market data, last close as of 18 Sept 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.